Company intelligence / Profile preview

MSN Pharmaceuticals

Hyderabad, Telangana, Indiamsnpi.com ↗

Ownership: Private
Employees: ~20000
Development stage: Other

Overview

MSN Pharmaceuticals has a broad commercial portfolio of over 450 APIs and 300+ finished dosage forms. The company has received approvals for several products globally—including first-to-launch generics—and supplies to more than 65 countries. Notable recent clinical results include approval of combination therapies for urology indications such as solifenacin succinate + mirabegron capsules for overactive bladder.

Therapeutic areas: NeurologyMen's HealthEndocrinologyOncologyGastroenterologyOtherNephrologyUrologyCardiovascular
Modalities: Small moleculePeptidesOligonucleotidesBiologic
Industry: Biotech

Partnerships

Operates as a contract manufacturer/CDMO for global pharma companies and supplies to >100 countries

Beyond the preview

Go deeper on MSN Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSN Pharmaceuticals.

Explore the full profile